- Home
- ASM vs NEO Comparison
ASM vs NEO Comparison
Compare ASM & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASM | NEO |
|---|---|---|
| Founded | 1968 | 2001 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Precision Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2005 | 2008 |
Fundamental Metrics
Financial Performance| Metric | ASM | NEO |
|---|---|---|
| Price | $6.59 | $8.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $8.18 | ★ $13.38 |
| AVG Volume (30 Days) | ★ 4.7M | 2.1M |
| Earning Date | 05-13-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.35 | $10.63 |
| Revenue Next Year | $34.26 | $9.73 |
| P/E Ratio | $67.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.85 | $4.72 |
| 52 Week High | $11.99 | $13.74 |
Technical Indicators
Market Signals| Indicator | ASM | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 43.72 | 47.92 |
| Support Level | $5.92 | $7.50 |
| Resistance Level | $8.06 | $8.84 |
| Average True Range (ATR) | 0.46 | 0.43 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 18.34 | 18.42 |
Price Performance
Historical ComparisonAbout ASM Avino Silver & Gold Mines Ltd. (Canada)
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.